Literature DB >> 15205451

Interleukin 1beta-induced production of H2O2 contributes to reduced sigmoid colonic circular smooth muscle contractility in ulcerative colitis.

Weibiao Cao1, Matthew D Vrees, Fabio M Potenti, Karen M Harnett, Claudio Fiocchi, Victor E Pricolo.   

Abstract

We have shown that neurokinin A-induced contraction of human sigmoid circular muscle (HSCM) is reduced in patients with ulcerative colitis and that interleukin (IL)-1beta may play a role in this change. We now examine changes in the signal transduction pathway mediating neurokinin A-induced contraction of HSCM and explore the role of IL-1beta and of H(2)O(2) in these changes. In Fura 2-AM-loaded ulcerative colitis HSCM cells, neurokinin A- and caffeine-induced peak Ca(2+) increase and cell shortening were significantly reduced. In normal cells, neurokinin A-induced contraction was decreased by protein kinase C inhibitor chelerythrine and by calmodulin inhibitor CGS9343B [1,3-dihydro-1-[1-[(4-methyl-4H,6H-pyrrolo[1,2-a][4,1]-benzoxazepin-4-yl)methyl]-4-piperidinyl]-2H-benzimidazol-2-one (1:1) maleate]. In ulcerative colitis muscle cells, contraction was inhibited only by chelerythrine but not by CGS9343B. IL-1beta treatment of normal HSCM strips and cells reproduced the changes observed in ulcerative colitis. IL-1beta-induced reduction in caffeine-induced peak Ca(2+) increase and contraction was reversed by catalase, suggesting a role of H(2)O(2). IL-1beta-induced H(2)O(2) production was inhibited by mitogen-activated protein kinase (MAPK) kinase inhibitor PD98059 (2'-amino-3'-methoxyflavone) and by cytosolic phospholipase A2 (cPLA(2)) inhibitor AACOCF3 (arachidonyltrifluoromethyl ketone), but neither by p38 MAPK inhibitor SB203580 [4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)-1H-imidazole] nor by nuclear factor-kappaB (NF-kappaB) inhibitory peptide NF-kappaB SN50 (H-Ala-Ala-Val-Ala-Leu-Leu-Pro-Ala-Val-Leu-Leu-Ala-Leu-Leu-Ala-Pro-Val-Gln-Arg-Lys-Arg-Gln-Lys-Leu-Met-Pro-OH). IL-1beta significantly increased the phosphorylation of extracellular signal-regulated kinase 1 (ERK1)/ERK2 MAPKs and cPLA(2) and IL-1beta-induced cPLA(2) phosphorylation was blocked by PD98059. We conclude that Ca(2+) stores of HSCM cells may be reduced in ulcerative colitis and that the signal transduction pathway of neurokinin A-induced contraction switches from calmodulin- and protein kinase C-dependent in normal cells to protein kinase C-dependent in ulcerative colitis cells. IL-1beta reproduces these changes, possibly by production of H(2)O(2) via sequential activation of MAPKs (ERK1/ERK2) and cPLA(2).

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15205451     DOI: 10.1124/jpet.104.068023

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  18 in total

1.  Immune/Inflammatory Response and Hypocontractility of Rabbit Colonic Smooth Muscle After TNBS-Induced Colitis.

Authors:  Yonggang Zhang; Fang Li; Hong Wang; Chaoran Yin; JieAn Huang; Sunila Mahavadi; Karnam S Murthy; Wenhui Hu
Journal:  Dig Dis Sci       Date:  2016-02-15       Impact factor: 3.199

2.  Hypercontractility of intestinal longitudinal smooth muscle induced by cytokines is mediated by the nuclear factor-κB/AMP-activated kinase/myosin light chain kinase pathway.

Authors:  Ancy D Nalli; Divya P Kumar; Sunila Mahavadi; Othman Al-Shboul; Reem Alkahtani; John F Kuemmerle; John R Grider; Karnam S Murthy
Journal:  J Pharmacol Exp Ther       Date:  2014-04-25       Impact factor: 4.030

3.  Changes in the expression of smooth muscle contractile proteins in TNBS- and DSS-induced colitis in mice.

Authors:  Reem Alkahtani; Sunila Mahavadi; Othman Al-Shboul; Shakir Alsharari; John R Grider; Karnam S Murthy
Journal:  Inflammation       Date:  2013-12       Impact factor: 4.092

4.  Cytokine-induced S-nitrosylation of soluble guanylyl cyclase and expression of phosphodiesterase 1A contribute to dysfunction of longitudinal smooth muscle relaxation.

Authors:  Senthilkumar Rajagopal; Ancy D Nalli; Divya P Kumar; Sayak Bhattacharya; Wenhui Hu; Sunila Mahavadi; John R Grider; Karnam S Murthy
Journal:  J Pharmacol Exp Ther       Date:  2014-12-30       Impact factor: 4.030

5.  Upregulation of RGS4 and downregulation of CPI-17 mediate inhibition of colonic muscle contraction by interleukin-1beta.

Authors:  Wenhui Hu; Sunila Mahavadi; Fang Li; Karnam S Murthy
Journal:  Am J Physiol Cell Physiol       Date:  2007-10-24       Impact factor: 4.249

6.  Interleukin-1 stimulates catabolism in C2C12 myotubes.

Authors:  Wei Li; Jennifer S Moylan; Melissa A Chambers; Jeffrey Smith; Michael B Reid
Journal:  Am J Physiol Cell Physiol       Date:  2009-07-22       Impact factor: 4.249

7.  Jun kinase-induced overexpression of leukemia-associated Rho GEF (LARG) mediates sustained hypercontraction of longitudinal smooth muscle in inflammation.

Authors:  Othman Al-Shboul; Ancy D Nalli; Divya P Kumar; Ruizhe Zhou; Sunila Mahavadi; John F Kuemmerle; John R Grider; Karnam S Murthy
Journal:  Am J Physiol Cell Physiol       Date:  2014-04-16       Impact factor: 4.249

8.  Impaired acetylcholine-induced smooth muscle contraction in colitis involves altered calcium mobilization and AKT phosphorylation.

Authors:  Ron W Wells; Sandra Lourenssen; Michael G Blennerhassett
Journal:  Pflugers Arch       Date:  2008-01-29       Impact factor: 3.657

9.  Upregulation of RGS4 expression by IL-1beta in colonic smooth muscle is enhanced by ERK1/2 and p38 MAPK and inhibited by the PI3K/Akt/GSK3beta pathway.

Authors:  Wenhui Hu; Fang Li; Sunila Mahavadi; Karnam S Murthy
Journal:  Am J Physiol Cell Physiol       Date:  2009-04-15       Impact factor: 4.249

10.  Cytokine-induced iNOS and ERK1/2 inhibit adenylyl cyclase type 5/6 activity and stimulate phosphodiesterase 4D5 activity in intestinal longitudinal smooth muscle.

Authors:  Sunila Mahavadi; Ancy D Nalli; Divya P Kumar; Wenhui Hu; John F Kuemmerle; John R Grider; Karnam S Murthy
Journal:  Am J Physiol Cell Physiol       Date:  2014-06-18       Impact factor: 4.249

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.